Scarica l'app Stockscreener
1.31
2.96%
-0.04
Dopo l'orario di chiusura:
1.31
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Precedente Chiudi:
$1.35
Aprire:
$1.35
Volume 24 ore:
546.96K
Relative Volume:
0.30
Capitalizzazione di mercato:
$246.14M
Reddito:
-
Utile/perdita netta:
$-222.39M
Rapporto P/E:
-0.9873
EPS:
-1.3268
Flusso di cassa netto:
$-193.40M
1 W Prestazione:
-5.76%
1M Prestazione:
-18.13%
6M Prestazione:
-57.05%
1 anno Prestazione:
-19.63%
Intervallo 1D:
$1.29
$1.36
Intervallo di 1 settimana:
$1.29
$1.445
Portata 52W:
$0.8302
$3.65
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Nome
Neumora Therapeutics Inc
Settore
Industria
Telefono
(857) 760-0900
Indirizzo
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.31 | 284.66M | 0 | -222.39M | -193.40M | -1.3268 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-17 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2026-01-12 | Iniziato | Leerink Partners | Outperform |
| 2025-12-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-09-16 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-03-10 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-07 | Downgrade | Stifel | Buy → Hold |
| 2025-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Hold |
| 2023-10-10 | Iniziato | BofA Securities | Buy |
| 2023-10-10 | Iniziato | Guggenheim | Buy |
| 2023-10-10 | Iniziato | JP Morgan | Overweight |
| 2023-10-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-10 | Iniziato | Stifel | Buy |
| 2023-10-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials - stocktwits.com
BlackRock Inc. Buys Shares of 7,791,869 Neumora Therapeutics, Inc. $NMRA - MarketBeat
Insiders Sold Neumora Therapeutics Prematurely At US$2.29 With Stock Trading Higher - simplywall.st
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
2,559,090 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by ICONIQ Capital LLC - MarketBeat
Neumora Therapeutics COO Aurora disposes of $269,966 in stock - Investing.com India
Daljit Singh Aurora Sells 21,055 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock - MarketBeat
Neumora Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Aurora Daljit Singh - Moomoo
Neumora Therapeutics (NMRA) grants chair 500K stock options - Stock Titan
Neumora Therapeutics (NASDAQ: NMRA) officer plans 41,608-share sale after August trades - Stock Titan
Replimune lands commercial chief after hard-fought approval; Neumora's Paul Berns sheds CEO title - Endpoints News
Mizuho maintains Outperform on Neumora, cuts target to $4 - scanx.trade
Neumora (NASDAQ: NMRA) officer plans cashless sale of 134K shares - Stock Titan
Neumora Therapeutics COO Daljit Aurora sells $431,674 in stock - Investing.com
Neumora Therapeutics COO Daljit Aurora sells $431,674 in stock By Investing.com - Investing.com South Africa
Neumora Therapeutics (NASDAQ:NMRA) Insider Daljit Singh Aurora Sells 31,000 Shares - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Insider Daljit Singh Aurora Sells 34,987 Shares - MarketBeat
Neumora Therapeutics (NMRA) insider plans new stock sale after $329K in recent trades - Stock Titan
Q3 EPS Estimate for Neumora Therapeutics Lifted by Analyst - MarketBeat
Neumora Therapeutics, Inc. Stock 12‑Month Price Target Raised to $6.67, Implies 307% Upside - TradingView
Neumora (NASDAQ: NMRA) insider to sell 69K more shares - Stock Titan
Neumora Therapeutics, Inc. (NMRA) Receives a Buy from RBC Capital - The Globe and Mail
Neumora (NASDAQ: NMRA) to sell 146K shares via Merrill Lynch - Stock Titan
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
H.C. Wainwright Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
1,849,445 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by Johnson & Johnson - MarketBeat
RBC Capital maintains Outperform on Neumora, cuts target to $5 - scanx.trade
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS) - The Globe and Mail
Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Wall Street Zen - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Neumora Therapeutics Appoints Joshua Pinto as CEO and Releases Q2 2026 Financial Results - Kalkine Media
Neumora Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
8-K: Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updatemoomoo - moomoo.com
Neumora Therapeutics Cuts Q2 Net Loss to $41.3M on Lower R&D Spend - Minichart
Neumora Appoints New CEO as Q2 Net Loss Narrows to $43.1M - Minichart
Form 8K Neumora Therapeutics Inc For: 14 August By Investing.com - Investing.com Australia
Levi & Korsinsky investigates Neumora after trial failure - scanx.trade
Neumora Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Neumora Therapeutics Q2 EPS of $(0.23) beats estimates - scanx.trade
Neumora Therapeutics 2Q 2026: Net loss $(43.1M), EPS $(0.23) — 10-Q Summary - TradingView
Neumora Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Neumora Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
NMRA: Pipeline advanced, net loss narrowed, and cash runway extends into Q3 2027 - TradingView
Neumora Therapeutics Reports Second Quarter 2026 Results and Advances Pipeline Amid Leadership Changes - Quiver Quantitative
Neumora Names Joshua Pinto CEO as 2026 Clinical Milestones Near - Stock Titan
Neumora Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Neumora Therapeutics (NMRA) Holds Above Key Support at $1.54 After Minor SlideForce Index - dars.gov.et
NMRA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutic - The National Law Review
Neumora Therapeutics Inc Azioni (NMRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):